Assays for investigating the impact of therapeutics on cells from patient blood and tissue
Celentyx Ltd maintains strategic relationships with local hospitals and clinics to enable assays to be performed using cells from patients within hours of isolation. This includes amongst others the Queen Elizabeth Hospital, the largest single-site hospital in the UK, and serves a large and diverse community covering many ethnic groups.
Celentyx has proprietary protocols to interrogate drug impact upon cells from tissues and/or blood from patients including working with cells purified from blood, slice cultures and/or performing assays on dissociated tissue cells. In general, assays are compatible with the Celentyx core platforms of multi-colour flow cytometry, high content confocal imaging and multiplex biomarker quantification (Luminex enabling analysis in 96- or 384-well formats.
Blood and tissues (when resected as part of the diagnostic/clinical pathway) are available from a wide range of cancers (e.g. breast, colon, head and neck, lung, ovarian, pancreatic, prostate), autoimmunity/inflammatory conditions (e.g. psoriasis, psoriatic arthritis, rheumatoid arthritis, SLE) and neurological diseases (e.g. Alzheimer’s disease, Parkinson’s disease).
Celentyx has proprietary protocols to interrogate drug impact upon cells from tissues and/or blood from patients including working with cells purified from blood, slice cultures and/or performing assays on dissociated tissue cells. In general, assays are compatible with the Celentyx core platforms of multi-colour flow cytometry, high content confocal imaging and multiplex biomarker quantification (Luminex enabling analysis in 96- or 384-well formats.
Blood and tissues (when resected as part of the diagnostic/clinical pathway) are available from a wide range of cancers (e.g. breast, colon, head and neck, lung, ovarian, pancreatic, prostate), autoimmunity/inflammatory conditions (e.g. psoriasis, psoriatic arthritis, rheumatoid arthritis, SLE) and neurological diseases (e.g. Alzheimer’s disease, Parkinson’s disease).
Flow cytometry
|
Intracellular cytokine staining in dissociated immune cell subsets arising from a biopsy taken from a patient with an inflammatory disease. Also see our dedicated flow cytometry page.
|
Phosphorylation of intracellular signaling molecules in immune cell subsets by phosphoflow. Also see our dedicated phosphoflow page.
|
Biomarker quantification by Luminex |
Imaging |
|
Time course of a range of biomarkers quantified in the plasma following test drug administration to patients. Also see our dedicated Luminex page.
|
Phagocytosis of a myelin-basic protein cargo by iMDM generated from monocytes isolated from for example patients with a neuroinflammatory disease.
|
|
|